

---

## **Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy**

- Indapta developing first-in-class, proprietary cancer therapy based on a specific, potent variety of Natural Killer immune cells for use in combination with multiple monoclonal antibodies
- Lonza to provide process development, clinical manufacturing and regulatory support for IND filing

### **Guy DiPierro, founder and chief executive officer of Indapta Therapeutics:**

“We believe our first-in-class, off-the-shelf, allogeneic G-NK cell therapy will drive the next critical phase in the evolution of cancer therapies following CAR T-cell therapies. Current autologous CAR T-cell therapies have proven efficacy in various hematologic cancers but have been beset with serious clinical and manufacturing challenges. By providing an off-the-shelf solution with our G-NK cell therapy, we can eliminate the need for a patient-specific therapy. Additionally, because our investigational cell therapies are not engineered, they are likely to be more effective, less costly and have a simpler regulatory pathway.”

### **Ronald Martell, co-founder and executive chairman, Indapta Therapeutics**

“Lonza, with its demonstrated expertise in cell therapy manufacturing, is the ideal strategic partner to help us advance our clinical program and scale the production of our G-NK cell therapy. We are currently completing Investigational New Drug-enabling studies and we plan to submit an IND application in late 2020 and initiate a first-in-human Phase 1/2 study in early 2021.”

### **Scott Waldman, Chief Strategy Officer, Lonza**

“Indapta’s world-class team of NK cell scientists and clinicians and cell therapy experts has created an innovative off-the-shelf immuno-oncology therapy based on a subset of cancer-killing NK cells that could make a truly meaningful impact in the treatment of hematologic malignancies and solid tumors.

### **Alberto Santagostino, SVP, Head of Cell & Gene Technologies, Lonza.**

“With our long-standing experience in cell therapy manufacturing, we are committed to providing Indapta with the expertise, resources and services it needs for cGMP manufacturing to advance its promising program into the clinic and beyond.”

**San Francisco (CA), USA and Basel, Switzerland, 10 January 2020** – Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic G-NK (FcRγ-deficient Natural Killer) cell therapy to treat multiple cancers, and Lonza today announced a strategic partnership.

Under the terms of the agreement, Lonza will manufacture Indapta's off-the-shelf, allogeneic G-NK cell therapy under current good manufacturing practices (cGMP) for use in clinical studies. Indapta will leverage Lonza's process development capabilities and expertise to ensure a robust, reproducible and scalable cGMP process. Process development and manufacturing will take place in Lonza's state-of-the-art cell and gene therapy manufacturing facility in Houston (TX), USA.

### **About Lonza**

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

### **About Indapta Therapeutics**

Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcεR1γ-deficient natural killer (NK) cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.

## **Lonza Contact Details**

### **Dr. Kristin Koehler**

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8782

[kristin.koehler@lonza.com](mailto:kristin.koehler@lonza.com)

### **Dr. Sanna Fowler**

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 8929

[sanna.fowler@lonza.com](mailto:sanna.fowler@lonza.com)

## **Indapta Contact Details**

### **Investors**

Guy DiPierro, CEO

917-282-9768

[gdipierro@indapta.com](mailto:gdipierro@indapta.com)

### **Media**

Nicole Raisch Goelz

408-568-4292

[ngoelz@w2ogroup.com](mailto:ngoelz@w2ogroup.com)

## **Additional Information and Disclaimer**

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.